Lecia Van Dam Sequist
Impact in
- Oncology top 0.01%
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 234
- Lung Cancer Diagnosis and Treatment 48
- Oncology 157
- Lung Cancer Research Studies 55
- Colorectal Cancer Treatments and Studies 39
- HER2/EGFR in Cancer Research 27
- Cancer Cells and Metastasis 22
- Co-authors
- Daniel A. Haber (25 shared papers)Rebecca Suk Heist (31 shared papers)Jeffrey A. Engelman (22 shared papers)Thomas James Lynch (25 shared papers)Mehmet Toner (15 shared papers)Alona Muzikansky (30 shared papers)Shyamala Maheswaran (13 shared papers)Daphne W. Bell (5 shared papers)
- Journals
- Journal of Thoracic Oncology (55 papers)Journal of Clinical Oncology (32 papers)Annals of Oncology (28 papers)Clinical Cancer Research (19 papers)Cancer Discovery (17 papers)
- Partner nations
- United StatesTaiwanCanada
In The Last Decade
Lecia Van Dam Sequist
344 papers receiving 61.4k citations
Lecia Van Dam Sequist's Hit Papers
Peers
Comparison fields: 5 of 180
- Oncology 30.2k
- Pulmonary and Respiratory Medicine 32.9k
- Cancer Research 14.7k
- Molecular Biology 18.3k
- Pathology and Forensic Medicine 3.0k
Countries citing papers authored by Lecia Van Dam Sequist
This map shows the geographic impact of Lecia Van Dam Sequist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lecia Van Dam Sequist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lecia Van Dam Sequist more than expected).
Fields of papers citing papers by Lecia Van Dam Sequist
This network shows the impact of papers produced by Lecia Van Dam Sequist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lecia Van Dam Sequist. The network helps show where Lecia Van Dam Sequist may publish in the future.
Co-authors
The 25 scholars most cited alongside Lecia Van Dam Sequist, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 348 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Hit paper breakdown → | 2010 | 3791 |
| 2 | Isolation of rare circulating tumour cells in cancer patients by microchip technology Hit paper breakdown → | 2007 | 3104 |
| 3 | Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Hit paper breakdown → | 2011 | 2915 |
| 4 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Hit paper breakdown → | 2013 | 2751 |
| 5 | Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition Hit paper breakdown → | 2013 | 2095 |
| 6 | Lung cancer Hit paper breakdown → | 2021 | 1840 |
| 7 | Isolation of circulating tumor cells using a microvortex-generating herringbone-chip Hit paper breakdown → | 2010 | 1429 |
| 8 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Hit paper breakdown → | 2014 | 1428 |
| 9 | Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Hit paper breakdown → | 2008 | 1421 |
| 10 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Hit paper breakdown → | 2015 | 1348 |
| 11 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Hit paper breakdown → | 2016 | 1199 |
| 12 | Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers Hit paper breakdown → | 2012 | 1103 |
| 13 | EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis Hit paper breakdown → | 2016 | 1058 |
| 14 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1010 |
| 15 | Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer Hit paper breakdown → | 2016 | 941 |
| 16 | Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells Hit paper breakdown → | 2013 | 936 |
| 17 | Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Hit paper breakdown → | 2010 | 899 |
| 18 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Hit paper breakdown → | 2015 | 829 |
| 19 | Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Hit paper breakdown → | 2016 | 775 |
| 20 | Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin Hit paper breakdown → | 2015 | 773 |
About Lecia Van Dam Sequist
Lecia Van Dam Sequist is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 348 papers that have together received 62.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (234 papers), Lung Cancer Research Studies (55 papers), Lung Cancer Diagnosis and Treatment (48 papers), Cancer Genomics and Diagnostics (47 papers), Colorectal Cancer Treatments and Studies (39 papers), HER2/EGFR in Cancer Research (27 papers), Cancer therapeutics and mechanisms (25 papers) and Cancer Cells and Metastasis (22 papers). The work is most often cited by research in Oncology (30.2k citations), Pulmonary and Respiratory Medicine (32.9k citations), Cancer Research (14.7k citations), Molecular Biology (18.3k citations) and Pathology and Forensic Medicine (3.0k citations). Lecia Van Dam Sequist has collaborated with scholars based in United States, Taiwan and Canada. Frequent co-authors include Daniel A. Haber, Rebecca Suk Heist, Jeffrey A. Engelman, Thomas James Lynch, Mehmet Toner, Alona Muzikansky, Shyamala Maheswaran, Daphne W. Bell, Justin F. Gainor and James Chih‐Hsin Yang. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.